External broker reports(aggregated public sources), CD Equisearch

CD Equisearch

External broker reports(aggregated public sources)

CD Equisearch is one of the leading brokerage houses with a strong presence in the institutional and HNI broking segment. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>On the back of destocking of inventory by Chinese companies and end user industry facing headwinds along with lower realization in key products, Balaji Amines revenue fell 34.6% from Rs 585.95 crs in Q3FY23 to Rs 383.36 crs in Q3FY24.</li><li>These headwinds also impacted the saleable volumes which saw a drop of 4.4% to 26,903 mt in Q3FY24 as against 28,147 mt in Q3FY23.</li><li>Volumes could however revive in the next few quarters as pharma &amp; API industry appears to have turned a corner.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

On the back of destocking of inventory by Chinese companies and end user industry facing headwinds along with lower realization in key products, Balaji Amines revenue fell 34.6% from Rs 585.95 crs in Q3FY23 to Rs 383.36 crs in Q3FY24.These headwinds also impacted the saleable volumes which saw a drop of 4.4% to 26,903 mt in Q3FY24 as against 28,147 mt in Q3FY23.Volumes could however revive in the next few quarters as pharma &amp; API industry appears to have turned a corner.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Balaji Amines Ltd (BAL) - Quarterly Highlights

India

Balaji Amines Ltd. manufactures methylamines, ethylamines, and derivatives of specialty chemicals and natural products. The Company supplies its products to c ompanies in the pharmaceutical and pesticide industries in India and elsewhere t hroughout the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Balaji Amines (BLA IN)

Balaji Amines Ltd (BAL) - Quarterly Highlights

On the back of destocking of inventory by Chinese companies and end user industry facing headwinds along with lower realization in key products,...

CD Equisearch

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)